Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals

AIDS Research and Human Retroviruses

Volumn 13, Issue 17, 1997, Pages 1509-1516

  Puppo, Francesco ^a,c   Brenci, Sabrina ^a   Bosco, Ornella ^a   Lanza, Lorella ^a   Barocci, Sergio ^b   Nocera, Arcangelo ^b   Ghio, Massimo ^a   Contini, Paola ^a   Setti, Maurizio ^a   Scudeletti, Marco ^a   Indiveri, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c DIMI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE;

EID: 0030770968     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1509     Document Type: Article

References (40)

1. Ploegh HL, Orr HT, and Strominger JL: Major histocompatibility antigens: The human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell 1981;24:287-299.
2. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, and Ferrone S: Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 1984;44:4679-4687.
3. Schumacher TNM, Heemels MT, Neefjes JJ, Kast WM, Melief CJM, and Ploegh HL: Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990;62:563-567.
4. Townsend A, Ohlén C, Bastin J, Ljunggren L, Foster L, and Kärre K: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (London) 1989;340: 443-448.
5. Zinkernagel RM and Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (London) 1974;248: 701-702.
6. Townsend A and Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-624.
7. Maudsley DJ and Pound JD: Modulation of MHC antigen expression by viruses and oncogenes. Immunol Today 1991;12:429-431.
8. Gooding LR: Virus proteins that counteract host immune defenses. Cell 1992;71:5-7.
9. Früh K, Ahn K, and Peterson PA: Inhibition of MHC class I antigen presentation by viral proteins. J Mol Med 1997;75:18-27.
10. Kerkau T, Schmitt-Landgraf R, Schimpl A, and Wecker E: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 1989;5:613-620.
11. + T cell line, CEM-E5, after HIV-1 infection. J Immunol 1989;143:2858-2866.
12. Noraz N, Verrier B, Fraisier C, and Desgranges C: Cell surface phenotypic changes induced in H9 T cells chronically infected with HTLV type I or HIV type 1 or coinfected with the two viruses. AIDS Res Hum Retroviruses 1995;11:145-154.
13. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993;41(RR17):1-13.
14. Böyum A: Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 1968;21(Suppl. 97):77-89.
15. Quarante V, Pellegrino MA, and Ferrone S: The monoclonal xenoantibody Q6/64 recognizes a determinant expressed by certain gene products of the A and B loci of the HLA region. Immunogenetics 1981;14:403-413.
16. Barnstable CJ, Bodmer WF, Brown G, Galfro G, Milstein C, Williams AF, and Ziegler AZ: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: New tools for genetic analysis. Cell 1978;14:9-20.
17. Pellegrino MA, Ng AK, Russo C, and Ferrone S: Heterologous distribution of determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 1982;34:18-23.
18. Quaranta V, Tanigaki N, and Ferrone S: Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human 1a-like alloantigens and on their subunits. Immunogenetics 1981;12:175-182.
19. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996;26:1-7.
20. + lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr 1997;14:158-162.
21. Benito J, Zabay JM, Gil J, Bermejo M, Escudero A, Sánchez E, and Fernández-Cruz E: Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: Changes in the expression of CD45RO, CD45RA, CD11b, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr 1997;14:128-135.
22. Howcroft TK, Strebel K, Martin MA, and Singer DS: Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 1993;260:1320-1322.
23. Howcroft TK, Palmer LA, Brown J, Rellahan B, Kashanchi F, Brady JN, and Singer DS: HIV Tat represses transcription through Spl-like elements in the basal promoter. Immunity 1995;3: 127-138.
24. Schwartz O, Maréchal V, Le Gall S, Lemonnier F, and Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Med 1996;2:338-342.
25. Chirmule N, Than S, Khan SA, and Pahwa S: Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J Virol 1995;69:492-498.
26. Fujinaga K, Zhong Q, Nakaya T, Kameoka M, Meguro T, Yamada K, and Ikuta K: Extracellular Nef protein regulates productive HIV-1 infection from latency. J Immunol 1995;155:5289-5298.
27. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher MB, Saag MS, Shaw GM, Quinn TC, Cohen OJ, Welbon CC, Pantaleo G, and Fauci AS: Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1996;93:4386-4391.
28. Clerici M and Shearer GM: A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
29. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, and Kiessling R: Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994;180:2371-2376.
30. van Bergen CAM, Smit WM, van Sluijters DA, Rijnbeek M, Willemze R, and Falkenburg JHF: Interleukin-10, interleukin-12, and tumor necrosis factor-α differentially influence the proliferation of human CD8+ and CD4+ T-cell clones. Ann Hematol 1996;72:245-252.
31. Nixon DF and McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991;5:1049-1059.
32. Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi B, Berzofsky JA, and Shearer GM: Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp120 in HIV-seropositive individuals. J Immunol 1991;146:2114-2219.
33. Langlade-Demoyen P, Michel F, Hoffenbach A, Vilmer E, Dadaglio G, Garcia-Pons F, Mayaud C, Autran B, Wain-Hobson S, and Plata F: Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J Immunol 1988; 141:1949-1957.
34. Chenciner N, Michel F, Dadaglio G, Langlade-Demoyen P, Hoffenbach A, Leroux A, Garcia-Pons F, Rautmann G, Guy B, Guillon JM, Mayaud C, Girard M, Autran B, Kieny MP, and Plata F: Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and mice. Eur J Immunol 1989;19:1537-1544.
35. Ferrari G, Humprey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
36. Sirianni MC, Soddus S, Malorni W, Aiancia G, and Aiuti F: Mechanism of defective natural killer activity in patients with AIDS is associated with defective distribution of tubulin. J Immunol 1988;140:2565-2568.
37. Brenner BG, Dascal A, Margolese RG, and Wainberg MA: Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukocyte Biol 1989;46:75-83.
38. Ljunggren K, Karlson A, Fenyö EM, and Jondal M: Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin Exp Immunol 1989;75:184-189.
39. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, and Pedersen BK: Defective natural immunity: An early manifestation of human immunodeficiency virus infection. J Exp Med 1995;182: 789-799.
40. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, and Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997;18:89-95.